NCCN Task Force Report: Prevention and Management of Mucositis in Cancer Care

Authors:
William Bensinger
Search for other papers by William Bensinger in
Current site
Google Scholar
PubMed Close
 MD
,
Mark Schubert
Search for other papers by Mark Schubert in
Current site
Google Scholar
PubMed Close
 DDS, MSD
,
Kie-Kian Ang
Search for other papers by Kie-Kian Ang in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
David Brizel
Search for other papers by David Brizel in
Current site
Google Scholar
PubMed Close
 MD
,
Elizabeth Brown
Search for other papers by Elizabeth Brown in
Current site
Google Scholar
PubMed Close
 MD
,
June G. Eilers
Search for other papers by June G. Eilers in
Current site
Google Scholar
PubMed Close
 RN, PhD
,
Linda Elting
Search for other papers by Linda Elting in
Current site
Google Scholar
PubMed Close
 DrPH
,
Bharat B. Mittal
Search for other papers by Bharat B. Mittal in
Current site
Google Scholar
PubMed Close
 MD
,
Mark A. Schattner
Search for other papers by Mark A. Schattner in
Current site
Google Scholar
PubMed Close
 MD
,
Ricardo Spielberger
Search for other papers by Ricardo Spielberger in
Current site
Google Scholar
PubMed Close
 MD
,
Nathaniel S. Treister
Search for other papers by Nathaniel S. Treister in
Current site
Google Scholar
PubMed Close
 DMD, DMSc
, and
Andy M. Trotti III
Search for other papers by Andy M. Trotti III in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 6: Issue S1
Online Publication Date:
Jun 2008
DOI:
https://doi.org/10.6004/jnccn.2008.2001
Restricted access

Oral mucositis (OM) has emerged as a common cause of dose delays and interruptions of cancer therapies such as multicycle chemotherapy, myeloablative chemotherapy, and radiotherapy with or without concurrent chemotherapy of head and neck cancer. Research into both preventive and management strategies has lagged behind research into the common cancer treatment–related morbidities of nausea, vomiting, and cytopenias. This disparity is related to the complex risk assessment of multifactorial patient and treatment factors and different techniques of rating mucositis. In addition, relatively few clinical trials have focused on mucositis as a specific outcome. Currently, the only effective preventive strategies include the use of palifermin to prevent OM in the setting of hematopoietic stem cell transplantation and oral cryotherapy used in conjunction with bolus 5-FU, melphalan, or edatrexate. For the most part, managing OM relies on supportive care and symptom palliation. However, OM is a common problem associated with significant patient morbidity and increased resource use. The magnitude of the problem demands innovative approaches based on expert judgment as evidence accumulates to support specific recommendations. To improve this situation, the NCCN convened a multidisciplinary task force to address key issues. This report integrates expert judgment with a review of key literature on risk assessment, prevention, and treatment strategies, and provides recommendations for the overall management of OM. (JNCCN 2008;6[Suppl 1]:S1–S21)

  • Collapse
  • Expand
  • 1.

    Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 2001;27(suppl):S3–11.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531–1539.

  • 3.

    Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201–2205.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Trotti A, Belim LA, Epstein JB, et al. Mucositis incidence, severity, and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253–262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Elting LS, Calais G, Selva N, et al. Patient-reported burden of mucosal injury: comparison of clinician-rated mucosal injury and patient reported outcomes [abstract]. J Clin Oncol 2007;25(Suppl 1): Abstract 9117.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231–234.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4: 277–284.

  • 8.

    Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2006;2:CD0000978.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820–831.

  • 10.

    Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000;110:292–299.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Robien K, Schubert MM, Bruemmer B, et al. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004;22:1268–1275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Mattsson T, Heimdahl A, Dahllof G, et al. Variables predicting oral mucosal lesions in allogenic bone marrow recipients. Head Neck 1991;13:224–229.

  • 13.

    Zerbe MB, Parkerson SG, Ortlieb ML, et al. Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs 1992;15:196–205.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Woo SB, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612–1617.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate and nonmethotrexate containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005;11:383–388.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcome, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 2007;68: 1110–1120.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 2006;106:329–336.

  • 18.

    Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and nonhaematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998;34:1871–1875.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Vokurka S, Bystrickaj E, Koza V, et al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study. Support Care Cancer 2006;14:974–976.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005;103:1165–1171.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002;94:1160–1167.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Raber-Durlacher JE, Weijl NI, Abu Saris M, et al. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer 2000;8: 366–371.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    McCarthy GM, Awde JD, Ghandi H, et al. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 1998;34:484–490.

  • 24.

    McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. Support Care Cancer 2006;14:541–547.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:1031–1035.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Svanberg A, Birgegaard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy—a randomized controlled trial. Support Care Cancer 2007;15:1155–1161.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 2005;13:266–269.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Tartarone A, Matera R, Romano G, et al. Prevention of high-dose melphalan-induced mucositis by cryotherapy. Leuk Lymphoma 2005;46:633–634.

  • 29.

    Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994;30B:234–236.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72:2234–2238.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Vokurka S, Bystricka E, Koza V, et al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT—results of a randomized multicentre study. Support Care Cancer 2005;13: 554–558.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Adamietz IA, Rahn R, Bottcher HD, et al. Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer 1998;6:373–377.

  • 33.

    Rahn R, Adamietz IA, Boettcher HD, et al. Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy. Dermatology 1997;195(Suppl 2):57–61.

  • 34.

    Ferretti GA, Ash RC, Brown AT, et al. Chlorhexidene for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 1987;114: 461–467.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo controlled double blind trial. Br J Cancer 1996;74: 312–317.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Okuno SH, Foote RL, Loprinzi CL, et al. A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 1997;79:2139–2149.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Wahlin Y. Effects of chlorhexidine mouth rinse on the oral health in patients with acute leukemia. Oral Surg Oral Med Oral Path 1989;68:279–287.

  • 38.

    Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganen HCL oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head and malignancy. Int J Radiat Oncol Biol Phy 2004;58:674–681.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Ertekin MV, Koc M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys 2004;58:167–174.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Cheng KK, Chang AM, Yuen MP. Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care. Eur J Cancer 2004;40:1208–1216.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Peterson DE, Jones JB, Petit RG. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007;109:322–331.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590–2598.

  • 43.

    Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186–5193.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007;13:806–813.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Luthi F, Berwert L, Frossard V, et al. Prevention of oral mucositis with palifermin in patients treated with high-dose chemotherapy and autologous stem cell transplantation: a single center experience [abstract]. Blood 2006;108:843a. Abstract 2974.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Kobbe G, Hieronimus N, Graef T, et al. Combined use of palifermin and pegfilgrastim significantly reduces toxicity of high-dose therapy and autologous blood stem cell transplantation in patients with multiple myeloma [abstract]. Blood 2006;108:406b. Abstract 5260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebocontrol trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108:3216–3222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Abdelaal AS, Barker DS, Fergusson MM. Treatment for irradiationinduced mucositis. Lancet 1989;1:97.

  • 49.

    Mascarin M, Franchin G, Minatel E, et al. The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol 1999;35:203–208.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Gordon B, Spadinger A, Hodges E, et al. Effect of granulocytemacrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 1994;12: 1917–1922.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Chi KH, Chen CH, Chan WK, et al. Effect of granulocytemacrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995;13:2620–2628.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Ryu JK, Swann S, LeVeque F, et al. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-inducted mucositis in had and neck cancer patients: a double blind placebocontrolled prospective phase III study of Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys 2007;67:643–650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Epstein JB, Silverman S Jr, Paggiarino DA, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 2001;92:875–885.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007;12: 738–747.

  • 55.

    Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006;64: 784–791.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Spencer A, Horvath N, Gibson J, et al. Prospective randomized trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005;35:971–977.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Phillips GL, Meisenberg BR, Reece DE, et al. Activity of singleagent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004;33:781–787.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002;30: 769–775.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Capelli D, Santini G, De Souza C, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000;110:300–307.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Antunes HS, de Azevedo AM, da Silva Bouzas LF, et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 2007;109: 2250–2255.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007:15;1145–1154.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Arun Maiya G, Sagar MS, Fernandes D. Effect of low level heliumneon (He-Ne) laser therapy in the prevention and treatment of radiation induced mucositis in head & neck cancer patients. Indian J Med Res 2006;124:399–402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract 2005;11: 139–143.

  • 64.

    Epstein JB, Epstein JD, Epstein MS, et al. Oral doxepin rinse: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth Analg 2006;103: 465–470.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Elting LS, Isitt J, Murphy BA, et al. Retrospective and prospective studies of the severity of oral mucositis (OM) in intensity modulated radiation therapy (IMRT) compared to conventional radiation therapy in head and neck cancer (HNC) patients. Intl Radiat Oncol Biol Phys 2006;66(Suppl 1):S447.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Nguyen NP, North D, Smith HJ, et al. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemoradiation. Surg Oncol 2006;15:199–203.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharamacogenetics of 5-FU based chemotherapy. Pharmacogenomics 2007;8:257–265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Sonis S, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 2007;43:289–300.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Kuo WP, Whipple ME, Epstein JB, et al. Deciphering gene expression profiles generated from DNA microarrays and their applications in oral medicine. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:584–591.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194–5200.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Schuster MW, Anaissie E, Hurd D, et al. Final analysis of the phase II, randomized, double blind, placebo-controlled trial of single dose velafermin (CG52135-05) for the prevention of oral mucositis [abstract]. J Clin Oncol 2006;24(Suppl 1):346s. Abstract 6537.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Chambers MS, Welsh DV, Scrimger RA, et al. RK-0202 for radiation induced oral mucositis [abstract]. J Clin Oncol 2006;24(Suppl 1):285s. Abstract 5523.

Copyright:
Copyright © 2008 by the National Comprehensive Cancer Network 2008
Article Category:
Research Article
Print Publication Date:
01 Jun 2008
Online Publication Date:
Jun 2008
Keywords:
NCCN Task Force Report; mucositis; chemotherapy; radiotherapy
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4915 1393 157
PDF Downloads 3747 1185 86
EPUB Downloads 0 0 0